<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36610206</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>06</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-2026</ISSN><JournalIssue CitedMedium="Internet"><Volume>81</Volume><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Asian journal of psychiatry</Title><ISOAbbreviation>Asian J Psychiatr</ISOAbbreviation></Journal><ArticleTitle>Real world research on transcranial magnetic stimulation treatment strategies for neuropsychiatric symptoms with long-COVID in Japan.</ArticleTitle><Pagination><StartPage>103438</StartPage><MedlinePgn>103438</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajp.2022.103438</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1876-2018(22)00436-1</ELocationID><Abstract><AbstractText>The number of patients suffering from long-COVID is currently increasing rapidly, even after the acute symptoms of COVID-19 have improved. The objective of this study was to investigate the effects of a pilot transcranial magnetic stimulation (TMS) treatment on neuropsychiatric symptoms caused by long-COVID. In this study, we examined the efficacy of the TMS treatment protocol, which has been established to be effective in refractory depression, by applying it to patients who sought TMS treatment for neuropsychiatric symptoms caused by long-COVID at TMS clinics in Tokyo, Japan in the context of the real world TMS registry study in Japan. Of the 23 patients (13 females) with long-COVID included in this case series, the main neuropsychiatric symptoms were chronic fatigue (n&#xa0;=&#xa0;12) and cognitive dysfunction (n&#xa0;=&#xa0;11), but most patients also showed mild depressive symptoms. The mean score on the Montgomery-&#xc5;sberg Depression Rating Scale before TMS treatment was 21.2, which improved to 9.8 after treatment. Similarly, the score on the Performance Status, which assesses the degree of fatigue, improved from 5.4 to 4.2, and the score on the Perceived Deficits Questionnaire-Depression 5-item, which reflects cognitive function, improved from 10.0 to 6.3. Although a few patients complained of pain at the stimulation site during the TMS as a side effect, there were no serious adverse events. Despite the limitations of this open-label pilot study, the TMS protocol implemented in this study may have beneficial effects on neuropsychiatric symptoms caused by long-COVID, including depressive symptoms, chronic fatigue, and cognitive impairment. These preliminary findings warrant further validation in randomized controlled trials.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noda</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Shinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. Electronic address: yoshi-tms@keio.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Akiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tokyo Yokohama TMS Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shichi</LastName><ForeName>Misaki</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Tokyo Yokohama TMS Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Ayano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Tokyo Yokohama TMS Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujii</LastName><ForeName>Kyoshiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iwasa</LastName><ForeName>Mio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Shinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagano</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Tokyo Yokohama TMS Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitahata</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Shinjuku-Yoyogi Mental Lab Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osawa</LastName><ForeName>Ryota</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Tokyo Yokohama TMS Clinic, Tokyo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Asian J Psychiatr</MedlineTA><NlmUniqueID>101517820</NlmUniqueID><ISSNLinking>1876-2018</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015673" MajorTopicYN="Y">Fatigue Syndrome, Chronic</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brain fog</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Chronic fatigue</Keyword><Keyword MajorTopicYN="N">Cognitive dysfunction</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">TMS</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that there is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>7</Day><Hour>18</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36610206</ArticleId><ArticleId IdType="pmc">PMC9795803</ArticleId><ArticleId IdType="doi">10.1016/j.ajp.2022.103438</ArticleId><ArticleId IdType="pii">S1876-2018(22)00436-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almutairi M.M., Sivandzade F., Albekairi T.H., Alqahtani F., Cucullo L. Neuroinflammation and its impact on the pathogenesis of COVID-19. Front. Med. 2021;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652056</ArticleId><ArticleId IdType="pubmed">34901061</ArticleId></ArticleIdList></Reference><Reference><Citation>Baeken C., Vanderhasselt M.A., Remue J., Herremans S., Vanderbruggen N., Zeeuws D., Santermans L., De Raedt R. Intensive HF-rTMS treatment in refractory medication-resistant unipolar depressed patients. J. Affect Disord. 2013;151:625&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pubmed">23896317</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker N., Shahab S., Giacobbe P., Blumberger D.M., Daskalakis Z.J., Kennedy S.H., Downar J. rTMS of the dorsomedial prefrontal cortex for major depression: safety, tolerability, effectiveness, and outcome predictors for 10 Hz versus intermittent theta-burst stimulation. Brain Stimul. 2015;8:208&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">25465290</ArticleId></ArticleIdList></Reference><Reference><Citation>Beam W., Borckardt J.J., Reeves S.T., George M.S. An efficient and accurate new method for locating the F3 position for prefrontal TMS applications. Brain Stimul. 2009;2:50&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2882797</ArticleId><ArticleId IdType="pubmed">20539835</ArticleId></ArticleIdList></Reference><Reference><Citation>Bliddal S., Banasik K., Pedersen O.B., Nissen J., Cantwell L., Schwinn M., Tulstrup M., Westergaard D., Ullum H., Brunak S., Tommerup N., Feenstra B., Geller F., Ostrowski S.R., Gronbaek K., Nielsen C.H., Nielsen S.D., Feldt-Rasmussen U. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci. Rep. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8222239</ArticleId><ArticleId IdType="pubmed">34162913</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberger D.M., Vila-Rodriguez F., Thorpe K.E., Feffer K., Noda Y., Giacobbe P., Knyahnytska Y., Kennedy S.H., Lam R.W., Daskalakis Z.J., Downar J. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391:1683&#x2013;1692.</Citation><ArticleIdList><ArticleId IdType="pubmed">29726344</ArticleId></ArticleIdList></Reference><Reference><Citation>Busatto G.F., de Araujo A.L., Castaldelli-Maia J.M., Damiano R.F., Imamura M., Guedes B.F., de Rezende Pinna F., Sawamura M.V.Y., Mancini M.C., da Silva K.R., Garcia M.L., Sumita N., Brunoni A.R., da Silva Duarte A.J., Burdmann E.A., Kallas E.G., Cerri G.G., Nitrini R., Bento R.F., Rocha V.G., de Souza H.P., Miguel E.C., de Carvalho C.R.R., Forlenza O.V., Batistella L.R., Group H.C.-S. Post-acute sequelae of SARS-CoV-2 infection: relationship of central nervous system manifestations with physical disability and systemic inflammation. Psychol. Med. 2022;52:2387&#x2013;2398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9151630</ArticleId><ArticleId IdType="pubmed">35521752</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzsaki G., Draguhn A. Neuronal oscillations in cortical networks. Science. 2004;304:1926&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pubmed">15218136</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C., Laurent E., Lemaignen A., Beaufils E., Bourbao-Tournois C., Laribi S., Flament T., Ferreira-Maldent N., Bruyere F., Stefic K., Gaudy-Graffin C., Grammatico-Guillon L., Bernard L. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 2021;27:258&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Nogo D., Carvalho I.P., Lee Y., Nasri F., Xiong J., Lui L.M.W., Subramaniapillai M., Gill H., Liu R.N., Joseph P., Teopiz K.M., Cao B., Mansur R.B., Lin K., Rosenblat J.D., Ho R.C., McIntyre R.S. Association between mood disorders and risk of COVID-19 infection, hospitalization, and death: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78:1079&#x2013;1091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8319830</ArticleId><ArticleId IdType="pubmed">34319365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Leber A., Jawad M.Y., Yu M., Lui L.M.W., Subramaniapillai M., Di Vincenzo J.D., Gill H., Rodrigues N.B., Cao B., Lee Y., Lin K., Mansur R.B., Ho R., Burke M.J., Rosenblat J.D., McIntyre R.S. Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Infect. Dis. 2022;54:467&#x2013;477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935463</ArticleId><ArticleId IdType="pubmed">35282780</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou S.H., Beghi E., Helbok R., Moro E., Sampson J., Altamirano V., Mainali S., Bassetti C., Suarez J.I., McNett M., Consortium G.C.-N., Consortium E. Global incidence of neurological manifestations among patients hospitalized with COVID-19-a report for the GCS-NeuroCOVID consortium and the ENERGY consortium. JAMA Netw. Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8114143</ArticleId><ArticleId IdType="pubmed">33974053</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators C.-M.D. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021;398:1700&#x2013;1712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8500697</ArticleId><ArticleId IdType="pubmed">34634250</ArticleId></ArticleIdList></Reference><Reference><Citation>Collantes M.E.V., Espiritu A.I., Sy M.C.C., Anlacan V.M.M., Jamora R.D.G. Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis. Can. J. Neurol. Sci. 2021;48:66&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7492583</ArticleId><ArticleId IdType="pubmed">32665054</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F., Carregari V.C., Veras F.P., Silva L.S., Nogueira M.H., Antunes A., Vendramini P.H., Valenca A.G.F., Brandao-Teles C., Zuccoli G.D.S., Reis-de-Oliveira G., Silva-Costa L.C., Saia-Cereda V.M., Smith B.J., Codo A.C., de Souza G.F., Muraro S.P., Parise P.L., Toledo-Teixeira D.A., Santos de Castro I.M., Melo B.M., Almeida G.M., Firmino E.M.S., Paiva I.M., Silva B.M.S., Guimaraes R.M., Mendes N.D., Ludwig R.L., Ruiz G.P., Knittel T.L., Davanzo G.G., Gerhardt J.A., Rodrigues P.B., Forato J., Amorim M.R., Brunetti N.S., Martini M.C., Benatti M.N., Batah S.S., Siyuan L., Joao R.B., Aventurato I.K., Rabelo de Brito M., Mendes M.J., da Costa B.A., Alvim M.K.M., da Silva Junior J.R., Damiao L.L., de Sousa I.M.P., da Rocha E.D., Goncalves S.M., Lopes da Silva L.H., Bettini V., Campos B.M., Ludwig G., Tavares L.A., Pontelli M.C., Viana R.M.M., Martins R.B., Vieira A.S., Alves-Filho J.C., Arruda E., Podolsky-Gondim G.G., Santos M.V., Neder L., Damasio A., Rehen S., Vinolo M.A.R., Munhoz C.D., Louzada-Junior P., Oliveira R.D., Rabelo de Brito F.Q., Nakaya H.I., Mauad T., Duarte-Neto A.N., Ferraz da Silva L.F., Dolhnikoff M., Saldiva P.H.N., Farias A.S., Cendes F., Moraes-Vieira P.M.M., Fabro A.T., Sebollela A., Proenca-Modena J.L., Yasuda C.L., Mori M.A., Cunha T.M., Martins-de-Souza D. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc. Natl. Acad. Sci. USA. 2022;119</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436354</ArticleId><ArticleId IdType="pubmed">35951647</ArticleId></ArticleIdList></Reference><Reference><Citation>Duprat R., Desmyter S., Rudi de R., van Heeringen K., Van den Abbeele D., Tandt H., Bakic J., Pourtois G., Dedoncker J., Vervaet M., Van Autreve S., Lemmens G.M., Baeken C. Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: a fast road to remission? J. Affect Disord. 2016;200:6&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">27107779</ArticleId></ArticleIdList></Reference><Reference><Citation>Feffer K., Fettes P., Giacobbe P., Daskalakis Z.J., Blumberger D.M., Downar J. 1Hz rTMS of the right orbitofrontal cortex for major depression: safety, tolerability and clinical outcomes. Eur. Neuropsychopharmacol. 2018;28:109&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">29153927</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehnel S.E., Forsyth B.H., DiBenedetti D.B., Danchenko N., Francois C., Brevig T. Patient-centered assessment of cognitive symptoms of depression. CNS Spectr. 2016;21:43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">24067243</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer A., Zhang L., Elbeji A., Wilmes P., Oustric P., Staub T., Nazarov P.V., Ollert M., Fagherazzi G. Long COVID symptomatology after 12 months and its impact on quality of life according to initial coronavirus disease 2019 disease severity. Open Forum Infect. Dis. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9379809</ArticleId><ArticleId IdType="pubmed">35983269</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., Corre F., Zarrouk V., Moyer J.D., Galy A., Honsel V., Fantin B., Nguyen Y. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham E.L., Clark J.R., Orban Z.S., Lim P.H., Szymanski A.L., Taylor C., DiBiase R.M., Jia D.T., Balabanov R., Ho S.U., Batra A., Liotta E.M., Koralnik I.J. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 "long haulers". Ann. Clin. Transl. Neurol. 2021;8:1073&#x2013;1085.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8108421</ArticleId><ArticleId IdType="pubmed">33755344</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A'Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A., Trender W., Chamberlain S.R., Jolly A.E., Grant J.E., Patrick F., Mazibuko N., Williams S.C., Barnby J.M., Hellyer P., Mehta M.A. Cognitive deficits in people who have recovered from COVID-19. EClinicalMedicine. 2021;39</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8298139</ArticleId><ArticleId IdType="pubmed">34316551</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao F., Tam W., Hu X., Tan W., Jiang L., Jiang X., Zhang L., Zhao X., Zou Y., Hu Y., Luo X., McIntyre R.S., Quek T., Tran B.X., Zhang Z., Pham H.Q., Ho C.S.H., Ho R.C.M. A quantitative and qualitative study on the neuropsychiatric sequelae of acutely ill COVID-19 inpatients in isolation facilities. Transl. Psychiatry. 2020;10:355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7570419</ArticleId><ArticleId IdType="pubmed">33077738</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes E.A., O'Connor R.C., Perry V.H., Tracey I., Wessely S., Arseneault L., Ballard C., Christensen H., Cohen Silver R., Everall I., Ford T., John A., Kabir T., King K., Madan I., Michie S., Przybylski A.K., Shafran R., Sweeney A., Worthman C.M., Yardley L., Cowan K., Cope C., Hotopf M., Bullmore E. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. Lancet Psychiatry. 2020;7:547&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159850</ArticleId><ArticleId IdType="pubmed">32304649</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtzheimer P.E., 3rd, McDonald W.M., Mufti M., Kelley M.E., Quinn S., Corso G., Epstein C.M. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress. Anxiety. 2010;27:960&#x2013;963.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020591</ArticleId><ArticleId IdType="pubmed">20734360</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., Luo J., Huang Z., Tu S., Zhao Y., Chen L., Xu D., Li Y., Li C., Peng L., Li Y., Xie W., Cui D., Shang L., Fan G., Xu J., Wang G., Wang Y., Zhong J., Wang C., Wang J., Zhang D., Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Jannati A., Oberman L.M., Rotenberg A., Pascual-Leone A. Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation. Neuropsychopharmacology. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9700722</ArticleId><ArticleId IdType="pubmed">36198876</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I.S., Chae Y. Exploring acupuncture actions in the body and brain. J. Acupunct. Meridian Stud. 2022;15:157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">35770545</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C.T., Cheng C.M., Chen M.H., Juan C.H., Tu P.C., Bai Y.M., Jeng J.S., Lin W.C., Tsai S.J., Su T.P. Antidepressant efficacy of prolonged intermittent theta burst stimulation monotherapy for recurrent depression and comparison of methods for coil positioning: a randomized, double-blind, sham-controlled study. Biol. Psychiatry. 2020;87:443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">31563272</ArticleId></ArticleIdList></Reference><Reference><Citation>Luber B., Lisanby S.H. Enhancement of human cognitive performance using transcranial magnetic stimulation (TMS) Neuroimage 85. 2014;85(Pt 3):961&#x2013;970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4083569</ArticleId><ArticleId IdType="pubmed">23770409</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda Y., Matsui T., Kataoka K., Fukada R., Fukuda S., Kuratsune H., Tajima S., Yamaguti K., Kato Y.H., Kiriike N. A two-year follow-up study of chronic fatigue syndrome comorbid with psychiatric disorders. Psychiatry Clin. Neurosci. 2009;63:365&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">19566769</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald W.M., Durkalski V., Ball E.R., Holtzheimer P.E., Pavlicova M., Lisanby S.H., Avery D., Anderson B.S., Nahas Z., Zarkowski P., Sackeim H.A., George M.S. Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression. Depress. Anxiety. 2011;28:973&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4413508</ArticleId><ArticleId IdType="pubmed">21898711</ArticleId></ArticleIdList></Reference><Reference><Citation>de Mello A.J., Moretti M., Rodrigues A.L.S. SARS-CoV-2 consequences for mental health: neuroinflammatory pathways linking COVID-19 to anxiety and depression. World J. Psychiatry. 2022;12:874&#x2013;883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9331446</ArticleId><ArticleId IdType="pubmed">36051596</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes-Ibarra M., Oliveira C.L.P., Orsso C.E., Landi F., Marzetti E., Prado C.M. The impact of long COVID-19 on muscle health. Clin. Geriatr. Med. 2022;38:545&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934728</ArticleId><ArticleId IdType="pubmed">35868672</ArticleId></ArticleIdList></Reference><Reference><Citation>Murta V., Villarreal A., Ramos A.J. Severe Acute Respiratory Syndrome Coronavirus 2 Impact on the Central Nervous System: Are Astrocytes and Microglia Main Players or Merely Bystanders? ASN Neuro. 2020;12 1759091420954960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7476346</ArticleId><ArticleId IdType="pubmed">32878468</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura Z.M., Nash R.P., Laughon S.L., Rosenstein D.L. Neuropsychiatric complications of COVID-19. Curr. Psychiatry Rep. 2021;23:25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7962429</ArticleId><ArticleId IdType="pubmed">33725218</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazari S., Azari Jafari A., Mirmoeeni S., Sadeghian S., Heidari M.E., Sadeghian S., Assarzadegan F., Puormand S.M., Ebadi H., Fathi D., Dalvand S. Central nervous system manifestations in COVID-19 patients: a systematic review and meta-analysis. Brain Behav. 2021;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994971</ArticleId><ArticleId IdType="pubmed">33421351</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y. Socioeconomical transformation and mental health impact by the COVID-19's ultimate VUCA era: toward the new normal, the New Japan, and the new world. Asian J. Psychiatr. 2020;54</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308027</ArticleId><ArticleId IdType="pubmed">32652489</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y., Izuno T., Tsuchiya Y., Hayasaka S., Matsumoto K., Murakami H., Ito A., Shinse Y., Suzuki A., Nakamura M. Acupuncture-induced changes of vagal function in patients with depression: a preliminary sham-controlled study with press needles. Complement Ther. Clin. Pract. 2015;21:193&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">26256139</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y., Zomorrodi R., Saeki T., Rajji T.K., Blumberger D.M., Daskalakis Z.J., Nakamura M. Resting-state EEG gamma power and theta-gamma coupling enhancement following high-frequency left dorsolateral prefrontal rTMS in patients with depression. Clin. Neurophysiol. 2017;128:424&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">28160748</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y., Zomorrodi R., Daskalakis Z.J., Blumberger D.M., Nakamura M. Enhanced theta-gamma coupling associated with hippocampal volume increase following high-frequency left prefrontal repetitive transcranial magnetic stimulation in patients with major depression. Int. J. Psychophysiol. 2018;133:169&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">30318052</ArticleId></ArticleIdList></Reference><Reference><Citation>Noda Y., Kizaki J., Takahashi S., Mimura M. TMS database registry consortium research project in Japan (TReC-J) for future personalized psychiatry. J. Pers. Med. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147312</ArticleId><ArticleId IdType="pubmed">35629266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes J.M., Kruger A., Proal A., Kell D.B., Pretorius E. The occurrence of hyperactivated platelets and fibrinaloid microclots in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Pharmaceuticals. 2022;15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9413879</ArticleId><ArticleId IdType="pubmed">36015078</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavli A., Theodoridou M., Maltezou H.C. Post-COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Arch. Med. Res. 2021;52:575&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8093949</ArticleId><ArticleId IdType="pubmed">33962805</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M.S., Kristiansen M.F., Hanusson K.D., Danielsen M.E., B A.S., Gaini S., Strom M., Weihe P. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin. Infect. Dis. 2021;73:e4058&#x2013;e4063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips S., Williams M.A. Confronting our next national health disaster - long-haul covid. N. Engl. J. Med. 2021;385:577&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pubmed">34192429</ArticleId></ArticleIdList></Reference><Reference><Citation>Renaud-Charest O., Lui L.M.W., Eskander S., Ceban F., Ho R., Di Vincenzo J.D., Rosenblat J.D., Lee Y., Subramaniapillai M., McIntyre R.S. Onset and frequency of depression in post-COVID-19 syndrome: a systematic review. J. Psychiatr. Res. 2021;144:129&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482840</ArticleId><ArticleId IdType="pubmed">34619491</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard M., Noiseux C., Desbeaumes Jodoin V., Blumberger D.M., Sheen J., Mansouri F., Elkrief L., Longpre-Poirier C., Lesperance P., Miron J.P. Prolonged intermittent theta burst stimulation in the treatment of major depressive disorder: a case series. Psychiatry Res. 2022;315</Citation><ArticleIdList><ArticleId IdType="pubmed">35816923</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Morales J., Guartazaca-Guerrero S., Rizo-Tellez S.A., Viurcos-Sanabria R., Barron E.V., Hernandez-Valencia A.F., Nava P., Escobedo G., Carrillo-Ruiz J.D., Mendez-Garcia L.A. Blood-brain barrier damage is pivotal for SARS-CoV-2 infection to the central nervous system. Exp. Neurobiol. 2022;31:270&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9471413</ArticleId><ArticleId IdType="pubmed">36050226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato W., Ono H., Matsutani T., Nakamura M., Shin I., Amano K., Suzuki R., Yamamura T. Skewing of the B cell receptor repertoire in myalgic encephalomyelitis/chronic fatigue syndrome. Brain Behav. Immun. 2021;95:245&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pubmed">33794313</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi S.H., Schaper F., Horn A., Hsu J., Padmanabhan J.L., Brodtmann A., Cash R.F.H., Corbetta M., Choi K.S., Dougherty D.D., Egorova N., Fitzgerald P.B., George M.S., Gozzi S.A., Irmen F., Kuhn A.A., Johnson K.A., Naidech A.M., Pascual-Leone A., Phan T.G., Rouhl R.P.W., Taylor S.F., Voss J.L., Zalesky A., Grafman J.H., Mayberg H.S., Fox M.D. Brain stimulation and brain lesions converge on common causal circuits in neuropsychiatric disease. Nat. Hum. Behav. 2021;5:1707&#x2013;1716.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688172</ArticleId><ArticleId IdType="pubmed">34239076</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumiyoshi T., Uchida H., Watanabe K., Oosawa M., Ren H., Moriguchi Y., Fujikawa K., Fernandez J. Validation and functional relevance of the short form of the perceived deficits questionnaire for depression for Japanese patients with major depressive disorder. Neuropsychiatr. Dis. Treat. 2022;18:2507&#x2013;2517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9639589</ArticleId><ArticleId IdType="pubmed">36353465</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Dercon Q., Luciano S., Geddes J.R., Husain M., Harrison P.J. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLOS Med. 2021;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M., Luciano S., Geddes J.R., Harrison P.J. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8:130&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Tate W., Walker M., Sweetman E., Helliwell A., Peppercorn K., Edgar C., Blair A., Chatterjee A. Molecular mechanisms of neuroinflammation in ME/CFS and long COVID to sustain disease and promote relapses. Front. Neurol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9174654</ArticleId><ArticleId IdType="pubmed">35693009</ArticleId></ArticleIdList></Reference><Reference><Citation>Thut G., Veniero D., Romei V., Miniussi C., Schyns P., Gross J. Rhythmic TMS causes local entrainment of natural oscillatory signatures. Curr. Biol. 2011;21:1176&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3176892</ArticleId><ArticleId IdType="pubmed">21723129</ArticleId></ArticleIdList></Reference><Reference><Citation>Zazzara M.B., Bellieni A., Calvani R., Coelho-Junior H.J., Picca A., Marzetti E. Inflammaging at the time of COVID-19. Clin. Geriatr. Med. 2022;38:473&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934712</ArticleId><ArticleId IdType="pubmed">35868667</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>